Susquehanna International Group, LLP Adma Biologics, Inc. Transaction History

Susquehanna International Group, LLP

$688 Billion
Q2 2025

A detailed history of Susquehanna International Group, LLP transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 484,717 shares of ADMA stock, worth $7.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

484,717

Previous 308,191 57.28%

Holding current value

$7.05 Million

Previous $6.11 Million 44.36%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$17.6 - $24.51 $3.11 Million - $4.33 Million	176,526 Added 57.28%	484,717 $8.83 Million
Q1 2025 May 14, 2025	BUY	$15.44 - $20.61 $2.25 Million - $3.01 Million	145,937 Added 89.94%	308,191 $6.11 Million
Q4 2024 Feb 14, 2025	BUY	$15.62 - $22.62 $1.57 Million - $2.27 Million	100,566 Added 163.02%	162,254 $2.78 Million
Q3 2024 Nov 14, 2024	SELL	$11.21 - $20.03 $178,810 - $319,498	-15,951 Reduced 20.55%	61,688 $1.23 Million
Q2 2024 Aug 15, 2024	SELL	$5.98 - $11.18 $531,119 - $992,962	-88,816 Reduced 53.36%	77,639 $868,000
Q1 2024 May 07, 2024	SELL	$4.4 - $6.74 $307,023 - $470,303	-69,778 Reduced 29.54%	166,455 $1.1 Million
Q4 2023 Feb 14, 2024	SELL	$3.08 - $4.52 $417,306 - $612,410	-135,489 Reduced 36.45%	236,233 $1.07 Million
Q3 2023 Nov 14, 2023	BUY	$3.47 - $4.61 $852,238 - $1.13 Million	245,602 Added 194.74%	371,722 $1.33 Million
Q2 2023 Aug 11, 2023	SELL	$3.12 - $4.22 $924,805 - $1.25 Million	-296,412 Reduced 70.15%	126,120 $465,000
Q1 2023 May 16, 2023	BUY	$3.01 - $3.87 $56,311 - $72,399	18,708 Added 4.63%	422,532 $1.4 Million
Q4 2022 Feb 14, 2023	SELL	$2.47 - $3.88 $116,186 - $182,511	-47,039 Reduced 10.43%	403,824 $1.57 Million
Q3 2022 Nov 14, 2022	BUY	$2.03 - $2.86 $11,434 - $16,110	5,633 Added 1.27%	450,863 $1.1 Million
Q2 2022 Aug 15, 2022	SELL	$1.43 - $2.2 $771,903 - $1.19 Million	-539,793 Reduced 54.8%	445,230 $882,000
Q1 2022 May 16, 2022	SELL	$1.28 - $1.83 $479,370 - $685,349	-374,508 Reduced 27.55%	985,023 $1.8 Million
Q4 2021 Feb 14, 2022	BUY	$1.09 - $1.66 $172,315 - $262,426	158,088 Added 13.16%	1,359,531 $1.92 Million
Q3 2021 Nov 15, 2021	BUY	$1.13 - $1.65 $625,742 - $913,694	553,754 Added 85.5%	1,201,443 $1.36 Million
Q2 2021 Aug 11, 2021	SELL	$1.51 - $2.07 $63,971 - $87,695	-42,365 Reduced 6.14%	647,689 $1.04 Million
Q1 2021 May 17, 2021	BUY	$1.67 - $2.95 $497,491 - $878,802	297,899 Added 75.96%	690,054 $1.21 Million
Q4 2020 Feb 16, 2021	BUY	$1.8 - $2.56 $476,829 - $678,156	264,905 Added 208.18%	392,155 $765,000
Q3 2020 Nov 16, 2020	SELL	$2.04 - $3.74 $130,435 - $239,131	-63,939 Reduced 33.44%	127,250 $304,000
Q2 2020 Aug 14, 2020	BUY	$2.42 - $3.29 $40,714 - $55,350	16,824 Added 9.65%	191,189 $560,000
Q1 2020 May 15, 2020	BUY	$1.5 - $4.59 $119,949 - $367,043	79,966 Added 84.71%	174,365 $502,000
Q4 2019 Feb 14, 2020	SELL	$3.89 - $5.15 $277,660 - $367,596	-71,378 Reduced 43.06%	94,399 $378,000
Q3 2019 Nov 14, 2019	BUY	$3.19 - $5.39 $97,917 - $165,446	30,695 Added 22.72%	165,777 $738,000
Q2 2019 Aug 16, 2019	BUY	$3.52 - $5.24 $11,014 - $16,395	3,129 Added 2.37%	135,082 $523,000
Q2 2019 Aug 14, 2019	BUY	$3.52 - $5.24 $400,987 - $596,925	113,917 Added 631.61%	131,953 $511,000
Q1 2019 May 15, 2019	BUY	$2.61 - $4.35 $47,073 - $78,456	18,036 New	18,036 $68,000
Q2 2018 Aug 14, 2018	SELL	$4.39 - $5.44 $414,749 - $513,949	-94,476 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$3.21 - $5.21 $303,267 - $492,219	94,476 New	94,476 $435,000

Others Institutions Holding ADMA

# of Institutions

400

Shares Held

196M

Call Options Held

2.08M

Put Options Held

1.56M

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $2.86B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Adma Biologics, Inc. Transaction History